The Galectin Intelligence Platform.

From Human Pathway Perturbation to Clinical Precision

Built on real-world patient biomarker and clinical data from Galectin-3 modulation, the platform converts every trial readout into sharper predictive models, leaner clinical designs, and new therapeutic targets.

The Galectin Intelligence Platform

A Self-Reinforcing Clinical & AI Flywheel

Every clinical readout sharpens our predictive models, refines trial design, and uncovers next-generation targets.

STEP 01

Drug

→
STEP 02

Human data

↑
Each trial makes the next one smarter.
↓
STEP 04

Better trials and new targets

←
STEP 03

AI

Platform Architecture & Clinical Applications

How Human Perturbation Data Drives Every Trial

Rather than training on synthetic assumptions, our computational stack ingests multi-dimensional clinical and biomarker readouts from TB006-treated patients to sharpen trial execution and antibody discovery.

End-to-End Computational Architecture

01 / HUMAN DATA INPUTS

Multi-Modal Clinical Readouts

Longitudinal plasma Galectin-3 kinetics (~9x target engagement), PK/PD profiles, inflammatory biomarker panels, and clinical cognitive/motor endpoints across neurodegenerative cohorts.

→
02 / MODELING LAYER

Trajectory & Subgroup Analytics

Baseline covariate modeling, untreated disease-trajectory forecasting, and multi-dimensional responder clustering built on real human pathway perturbation.

→
03 / CLINICAL OUTPUTS

Trial & Pipeline Execution

Prognostic covariate adjustment for leaner Phase 2/3 trials, biomarker-guided inclusion criteria, and epitope prioritization for next-generation antibodies.

Trial Sensitivity & Power

Prognostic digital twins

For each trial participant, the platform models the disease trajectory they would most likely follow without treatment based on baseline clinical and biomarker covariates. Incorporating these prognostic scores reduces unexplained outcome variance—enabling smaller sample sizes and higher statistical confidence under regulatory-qualified prognostic frameworks.

Pipeline Application: Informing covariate-adjusted analysis and trial design across our 210-patient Phase 2b Alzheimer’s study (TB006-AD-2105) and future pivotal programs.
Precision Stratification

Responder enrichment

Neuroinflammatory and neurodegenerative patients do not respond uniformly. By mining longitudinal human datasets from completed Phase 1b/2a studies and ongoing Phase 2 cohorts, the platform identifies baseline biomarker and clinical signatures linked to stronger Gal-3 target engagement and clinical benefit—preventing signal dilution in subsequent trials.

Pipeline Application: Translating multi-indication human response patterns across Alzheimer’s and Parkinson’s trials into sharper patient-selection criteria.
Next-Gen Antibodies

Human-first target discovery

Pharmacological neutralization of Galectin-3 in people provides a direct, in vivo readout of how the pathway regulates chronic inflammation and protein aggregation in human biology. The platform analyzes downstream biomarker shifts to guide affinity and epitope engineering for next-generation Gal-3 antibodies and uncover adjacent pathway targets.

Pipeline Application: Extending insights from systemic and CNS Gal-3 modulation into follow-on biologics and new therapeutic indications.
Scientific Discipline & Guardrails

What the Platform Is Not

TrueBinding treats artificial intelligence as an instrument for rigorous biology—never a substitute for experimental or clinical proof.

01 / Wet-Lab First

Not a replacement for wet-lab validation

Computational predictions generate hypotheses, not proof. No AI-derived antibody candidate or target insight advances without rigorous biochemical, cellular, and in vivo validation.

02 / Evidence-Earned

Not a promise beyond the data

We do not treat algorithms as black-box oracles or extrapolate past what human biology supports. Every prognostic model and responder signature must be earned through reproducible clinical readouts.

03 / Measured Impact

Not unmeasured efficiency claims

We do not publish hypothetical timeline cuts or speculative cost-reduction projections. Operational and trial-design gains are reported only after they are empirically measured in prospective studies.

Our Mandate: The platform’s job is to make the science faster and the trials sharper—strictly on evidence.

Founder & Leadership

George Hong

Founder & Chief Executive Officer

Education M.S. in Computer Science, University of Arizona
AI Infrastructure Leadership CEO, Wangsu Technology (SZSE: 300017) — leading its pivot into AI infrastructure for AI models
TrueBinding Founded in 2016
Healthcare Investment Portfolio
Ceribell Neurovasc Arrinex Devoro Lucira
Data-Native Leadership

Why a Computer Scientist Founded a Biotech

“Drug development’s bottleneck is no longer chemistry — it is knowing which patients, which trials, and which targets. The company is built the way a data company is built: the drug generates the data, and the data improves the drug.”

George Hong founded TrueBinding in 2016 on that simple observation. That closed-loop architecture is the Galectin Intelligence Platform, and it is the reason a computer scientist built a clinical-stage biotechnology company.

Alongside leading TrueBinding, he serves as Chief Executive Officer of Wangsu Technology (SZSE: 300017), where he is spearheading the company’s strategic transformation into large-scale AI infrastructure for AI models—bringing deep systems-engineering and data-platform discipline directly into therapeutic development.